D. Mclornan

N. Kröger, L. Kanz, M. Robin, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Combination therapy with ruxolitinib plus 5‐azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast‐phase myeloproliferative neoplasms

C. Harrison, D. Mclornan, K. Raj, 2014, British journal of haematology.

Guideline for the investigation and management of eosinophilia

B. Bain, A. Mead, N. Cross, 2017, British journal of haematology.

Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT

M. Robin, I. Yakoub-Agha, J. Byrne, 2022, British journal of haematology.

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper.

S. Montoto, M. Beksac, D. Mclornan, 2022, The Lancet. Haematology.

Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis.

G. Mufti, D. Mclornan, O. Malik, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia

N. Cross, C. Harrison, D. Mclornan, 2017, Haematologica.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

H. Einsele, N. Kröger, M. Robin, 2019, Haematologica.

Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT

J. Johansson, N. Kröger, S. Iacobelli, 2020, British journal of haematology.

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy

G. Mufti, A. Lennartsson, M. Jansson, 2015, Oncotarget.

Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party

M. Robin, I. Yakoub-Agha, M. Aljurf, 2021, Leukemia.

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis

N. Kröger, M. Robin, P. Chevallier, 2021, Bone Marrow Transplantation.

Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.

P. Bartolomeo, M. Robin, I. Yakoub-Agha, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT

N. Kröger, M. Robin, I. Yakoub-Agha, 2015, British journal of haematology.

Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT

D. Mclornan, C. Gurnari, 2022, Bone Marrow Transplantation.

Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

G. Mufti, D. Mclornan, H. de Lavallade, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Current and future status of JAK inhibitors

C. Harrison, D. Mclornan, J. Gotlib, 2021, The Lancet.

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.

T. Barbui, M. Robin, I. Yakoub-Agha, 2022, The Lancet. Haematology.

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia

M. Malim, D. Mclornan, C. Graham, 2021, British journal of haematology.

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

M. Malim, C. Harrison, D. Mclornan, 2021, Leukemia.

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital.

G. Mufti, D. Mclornan, H. de Lavallade, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms.

Soma Das, G. Mufti, Xingmin Feng, 2018, Blood advances.

RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis

G. Mufti, D. Mclornan, T. Seidl, 2016, Oncotarget.

Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms

D. Mclornan, Ferdinand von Meyenn, R. Oakey, 2021, Genome research.

Applying synthetic lethality for the selective targeting of cancer.

G. Mufti, D. Mclornan, Ghulam J Mufti, 2014, The New England journal of medicine.

Molecular mechanisms of drug resistance in acute myeloid leukaemia

P. Johnston, D. Longley, M. McMullin, 2007, Expert opinion on drug metabolism & toxicology.

Pacritinib: a new agent for the management of myelofibrosis?

C. Harrison, D. Mclornan, Y. Beauverd, 2015, Expert opinion on pharmacotherapy.

GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML

J. Fitzgibbon, T. Vulliamy, J. Cavenagh, 2018, Leukemia.

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012

A. Mead, C. Harrison, D. Mclornan, 2012, British journal of haematology.

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis

A. Mead, A. Godfrey, M. McMullin, 2018, British journal of haematology.

Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT

R. Fanin, P. Chiusolo, I. Yakoub-Agha, 2021, Bone Marrow Transplantation.

Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.

G. Mufti, D. Mclornan, Stephanie J. Lee, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Variable Penetrance Is Linked with Monoallelic Gene Expression in Inherited GATA2-Mutated MDS/AML

J. Fitzgibbon, T. Vulliamy, J. Cavenagh, 2016 .

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience

I. Yakoub-Agha, J. Byrne, J. Passweg, 2022, Haematologica.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

M. Caligiuri, C. Lengerke, B. Becher, 2018, Nature Medicine.

Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis

I. Yakoub-Agha, D. Mclornan, A. Radujkovic, 2022, British journal of haematology.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Angela G. Fleischman, A. Salar, S. Verstovsek, 2023, The Lancet.

Alemtuzumab vs anti‐thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning

G. Mufti, S. Chevret, M. Robin, 2018, European journal of haematology.

Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML

M. Malim, D. Mclornan, C. Graham, 2021, medRxiv.

Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT

N. Kröger, S. Iacobelli, M. Robin, 2021, Bone Marrow Transplantation.

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients

M. Malim, D. Mclornan, K. Doores, 2021, Cancer Cell.

Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)

G. Mufti, D. Mclornan, H. de Lavallade, 2019, Bone Marrow Transplantation.

MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor.

S. Verstovsek, R. Donahue, R. Mesa, 2022, Clinical lymphoma, myeloma & leukemia.

Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?

C. Harrison, D. Mclornan, A. Khan, 2015, British journal of haematology.

Principles of haematopoietic stem cell transplantation

D. Mclornan, 2013 .

Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey

J. Snowden, H. Baldomero, J. Passweg, 2023, Bone Marrow Transplantation.

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

N. Kröger, S. Iacobelli, L. Kanz, 2020, Leukemia.

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype

D. Mclornan, H. de Lavallade, K. Raj, 2022, British journal of haematology.

Clinicopathological characterisation of myeloproliferative neoplasm‐unclassifiable (MPN‐U): a retrospective analysis from a large UK tertiary referral centre

C. Harrison, D. Mclornan, J. O'Sullivan, 2021, British journal of haematology.

Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

J. Bourhis, M. Robin, I. Yakoub-Agha, 2023, American journal of hematology.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

M. Arcasoy, S. Verstovsek, D. Mclornan, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

M. Robin, I. Yakoub-Agha, J. Byrne, 2022, American journal of hematology.

Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization

M. Cazzola, G. Mufti, D. Mclornan, 2017 .

Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice.

C. Harrison, D. Mclornan, R. Hargreaves, 2022, Current research in translational medicine.

Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT

M. Robin, I. Yakoub-Agha, J. Snowden, 2022, Bone Marrow Transplantation.

Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature.

M. Simpson, G. Mufti, K. Mills, 2021, Blood advances.

Ruxolitinib for the Treatment of Essential Thrombocythemia

C. Harrison, D. Mclornan, D. Radia, 2018, HemaSphere.

Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT

I. Yakoub-Agha, J. Snowden, M. Sever, 2019, Bone Marrow Transplantation.

'Fine tuning' Conditioning Protocols for Myelofibrosis to Reduce Graft Failure: are we making progress?

D. Mclornan, 2022, Transplantation and cellular therapy.

Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer

U. McDermott, P. Johnston, D. Longley, 2010, Clinical Cancer Research.

Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms

C. Harrison, D. Mclornan, D. Radia, 2017, British journal of haematology.

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients

M. Malim, D. Mclornan, K. Doores, 2021, Cancer Cell.

Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021

C. Harrison, D. Mclornan, J. O'Sullivan, 2021, HemaSphere.

Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms

C. Harrison, D. Mclornan, R. Dillon, 2020, British journal of haematology.

Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis

C. Harrison, D. Mclornan, S. Alimam, 2016, British journal of haematology.

Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib

A. Mead, A. Godfrey, D. Mclornan, 2022, Blood.

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

A. Mead, S. Verstovsek, M. McMullin, 2022, Blood.

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

S. Verstovsek, R. Donahue, A. Vannucchi, 2022, Blood.

JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells

G. Mufti, C. Harrison, D. Mclornan, 2015, British journal of haematology.

Principles of haemopoietic stem cell transplantation

D. Mclornan, R. Dowse, 2017, Medicine.

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies

A. Mead, S. Verstovsek, R. Donahue, 2023, Cancer medicine.

The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT

J. Gribben, J. Johansson, P. Chevallier, 2023, Bone marrow transplantation.

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.

J. Bourhis, R. Fanin, N. Kröger, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pneumonitis post-haematopoeitic stem cell transplant - cytopathology clinches diagnosis.

D. Mclornan, P. Menon, K. Raj, 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Sweet’s syndrome with pulmonary involvement

D. Mclornan, S. Halpern, S. Mehrtens, 2019, BMJ Case Reports.

Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

C. Harrison, D. Mclornan, D. Radia, 2016, Future oncology.

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib

M. Malim, D. Mclornan, K. Doores, 2022, Blood Cancer Journal.

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders

M. Malim, C. Harrison, D. Mclornan, 2022, Blood Advances.

Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

K. Rezvani, C. Harrison, D. Mclornan, 2020 .

An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

S. Iacobelli, P. Chevallier, I. Yakoub-Agha, 2023, Bone Marrow Transplantation.

Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience

C. Harrison, D. Mclornan, J. Desterro, 2019, British journal of haematology.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

A. Stamatoullas, M. Robin, I. Yakoub-Agha, 2022, Bone Marrow Transplantation.

Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?

D. Mclornan, A. Rampotas, N. Polverelli, 2023, British journal of haematology.

Anti‐type M phospholipase A2 receptor antibody‐positive membranous nephropathy as a part of multi‐system autoimmune syndrome post‐allogeneic stem cell transplantation

G. Mufti, D. Mclornan, H. de Lavallade, 2018, Internal medicine journal.

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.

J. Bourhis, I. Yakoub-Agha, D. Mclornan, 2023, Bone marrow transplantation.

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

I. Yakoub-Agha, M. Aljurf, R. Gale, 2023, Blood advances.

Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy

I. Yakoub-Agha, J. Snowden, D. Mclornan, 2023, Bone Marrow Transplantation.

Guideline for the investigation and management of eosinophilia

B. Bain, A. Mead, N. Cross, 2017, British journal of haematology.

Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

G. Mufti, D. Mclornan, H. de Lavallade, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT.

M. Voso, M. Robin, M. Wlodarski, 2023, The Lancet. Haematology.

HYDROXYCARBAMIDE EFFECT ON DNA METHYLATION AND GENE EXPRESSION IN MYELOPROLIFERATIVE NEOPLASMS: A CROSS-SPECIES STUDY

D. Mclornan, A. Mullally, Stephania Contreras-Castillo, 2021 .

Graft-versus-Host Disease Prophylaxis with Post Transplant Cyclophosphamide in Chronic Myeloid Leukemia patients undergoing Allogeneic Hematopoietic Cell Transplant from either an Unrelated or Mismatched Related Donor: a comparative study from the Chr....

I. Yakoub-Agha, D. Mclornan, L. Griškevičius, 2023, Transplantation and cellular therapy.

Safety evaluation of ruxolitinib for treating myelofibrosis

C. Harrison, D. Mclornan, S. Galli, 2014, Expert opinion on drug safety.

Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms

C. Harrison, D. Mclornan, D. Radia, 2017, British Journal of Haematology.

Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.

M. Griesshammer, M. Robin, G. Barosi, 2023, The Lancet Haematology.

Applying synthetic lethality for the selective targeting of cancer.

G. Mufti, D. Mclornan, A. List, 2014, The New England journal of medicine.

N. Kröger, S. Iacobelli, M. Robin, 2019, Bone Marrow Transplantation.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT

N. Kröger, M. Robin, I. Yakoub-Agha, 2018, British journal of haematology.